SCM
TBPH icon

Sterling Capital Management’s Theravance Biopharma TBPH Stock Holding History

Sterling Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.44K Sell
261
-14,795
-98% -$245K ﹤0.01% 2686
2026
Q1 		$244K Sell
15,056
-8,614
-36% -$152K ﹤0.01% 1090
2025
Q4 		$443K Buy
23,670
+54
+0.2% +$896 0.01% 995
2025
Q3 		$345K Buy
23,616
+23,342
+8,519% +$295K 0.01% 1141
2025
Q2 		$3.02K Sell
274
-368
-57% -$3.58K ﹤0.01% 2782
2025
Q1 		$5.73K Sell
642
-534
-45% -$4.97K ﹤0.01% 2094
2024
Q4 		$11.1K Buy
1,176
+1,059
+905% +$9.64K ﹤0.01% 2116
2024
Q3 		$943 Buy
+117
New +$1.01K ﹤0.01% 2560

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Sterling Capital Management's TBPH Position: Q2 2026 in Review

Sterling Capital Management reduced its Theravance Biopharma (TBPH) stake by 98% in Q2 2026, selling an estimated $245K and leaving 261 shares worth $4.44K. The position accounts for ﹤0.01% of the portfolio, ranked #2686.

Sterling Capital Management first reported a position in TBPH in Q3 2024 and has held it in 8 quarters since. The position peaked at $443K in Q4 2025. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Sterling Capital Management held 261 shares of Theravance Biopharma worth $4.44K as of Q2 2026.
  • Sterling Capital Management sold 14,795 Theravance Biopharma shares in Q2 2026, an estimated $245K.
  • Theravance Biopharma made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2686 holding.
  • Sterling Capital Management first reported a position in Theravance Biopharma in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Theravance Biopharma position peaked at $443K in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.